Skip to main content

Lazertinib Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 10, 2025.

Applies to lazertinib: oral tablets.

Side effects include:

Most common adverse reactions (≥20%) of lazertinib in combination with amivantamab: rash, nail toxicity, infusion-related reaction (amivantamab), musculoskeletal pain, edema, stomatitis, VTE, paresthesia, fatigue, diarrhea, constipation, COVID-19, hemorrhage, dry skin, decreased appetite, pruritus, nausea, ocular toxicity.

Most common Grade 3 or 4 laboratory abnormalities (≥2%) of lazertinib in combination with amivantamab: decreased albumin, decreased sodium, increased ALT, decreased potassium, decreased hemoglobin, increased AST, increased GGT, increased magnesium.

For healthcare professionals

Applies to lazertinib: oral tablet.

General adverse events

All the reported adverse events are those described in patients who received this drug in combination with amivantamab. The most common adverse events (all grades) were rash, nail toxicity, musculoskeletal pain, edema, stomatitis, venous thromboembolism, paresthesia, fatigue, constipation, COVID-19, hemorrhage, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity.[Ref]

Cardiovascular

Dermatologic

Gastrointestinal

Hematologic

Hepatic

Musculoskeletal

Nervous system

Ocular

Psychiatric

Renal

Respiratory

Metabolic

Other

References

1. (2024) "Product Information. Lazcluze (lazertinib)." Janssen Biotech, Inc.

Further information

Lazertinib side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.